(Reuters) - Corcept Therapeutics Inc lost more than half its market value after the company said it would stop a late-stage trial of its depression drug to focus on more promising programs. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/czlJc9fsZPk/story01.htm
Read More
No comments:
Post a Comment